Lördag 22 Februari | 09:23:25 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-02-16 08:30 Bokslutskommuniké 2025
2025-11-03 08:30 Kvartalsrapport 2025-Q3
2025-08-29 08:30 Kvartalsrapport 2025-Q2
2025-05-30 N/A X-dag ordinarie utdelning IZAFE B 0.00 SEK
2025-05-28 N/A Årsstämma
2025-04-25 08:30 Kvartalsrapport 2025-Q1
2025-02-14 - Bokslutskommuniké 2024
2024-11-01 - Kvartalsrapport 2024-Q3
2024-08-30 - Kvartalsrapport 2024-Q2
2024-05-31 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2024-05-30 - Årsstämma
2024-04-26 - Kvartalsrapport 2024-Q1
2024-02-09 - Bokslutskommuniké 2023
2023-12-21 - Extra Bolagsstämma 2024
2023-11-17 - Kvartalsrapport 2023-Q3
2023-08-25 - Kvartalsrapport 2023-Q2
2023-05-12 - Kvartalsrapport 2023-Q1
2023-04-06 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2023-04-05 - Årsstämma
2023-02-03 - Bokslutskommuniké 2022
2022-11-07 - Kvartalsrapport 2022-Q3
2022-10-05 - Extra Bolagsstämma 2022
2022-08-26 - Kvartalsrapport 2022-Q2
2022-06-15 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2022-06-14 - Årsstämma
2022-04-29 - Kvartalsrapport 2022-Q1
2022-02-18 - Bokslutskommuniké 2021
2021-11-29 - Kvartalsrapport 2021-Q3
2021-09-23 - Extra Bolagsstämma 2021
2021-08-30 - Kvartalsrapport 2021-Q2
2021-06-28 - Årsstämma
2021-06-15 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2021-04-29 - Kvartalsrapport 2021-Q1
2021-02-19 - Bokslutskommuniké 2020
2020-11-09 - Kvartalsrapport 2020-Q3
2020-08-17 - Kvartalsrapport 2020-Q2
2020-06-26 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2020-06-25 - Årsstämma
2020-05-11 - Kvartalsrapport 2020-Q1
2020-02-20 - Bokslutskommuniké 2019
2019-05-10 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2019-05-06 - Kvartalsrapport 2019-Q1
2019-04-10 - Årsstämma
2019-02-28 - Bokslutskommuniké 2018
2018-12-18 - Extra Bolagsstämma 2018
2018-10-24 - Kvartalsrapport 2018-Q3
2018-08-29 - Kvartalsrapport 2018-Q2
2018-05-24 - Kvartalsrapport 2018-Q1
2018-04-12 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2018-04-11 - Årsstämma
2018-03-22 - Bokslutskommuniké 2017
2017-08-29 - Kvartalsrapport 2017-Q2
2017-05-09 - Kvartalsrapport 2017-Q1
2017-04-26 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2017-04-25 - Årsstämma
2017-02-24 - Bokslutskommuniké 2016
2016-11-16 - Kvartalsrapport 2016-Q3
2016-10-19 - Extra Bolagsstämma 2016
2016-08-31 - Kvartalsrapport 2016-Q2
2016-04-20 - Kvartalsrapport 2016-Q1
2016-02-25 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2016-02-24 - Årsstämma
2016-02-04 - Bokslutskommuniké 2015
2015-11-13 - Kvartalsrapport 2015-Q3
2015-09-04 - Kvartalsrapport 2015-Q2
2015-07-22 - Extra Bolagsstämma 2015
2015-05-07 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2015-05-06 - Årsstämma
2015-04-17 - Kvartalsrapport 2015-Q1
2015-02-20 - Bokslutskommuniké 2014
2014-12-17 - Extra Bolagsstämma 2014
2014-11-28 - Kvartalsrapport 2014-Q3
2014-11-14 - Kvartalsrapport 2014-Q3
2014-08-29 - Kvartalsrapport 2014-Q2
2014-06-12 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2014-06-11 - Årsstämma
2014-05-16 - Kvartalsrapport 2014-Q1
2014-02-21 - Bokslutskommuniké 2013
2013-11-15 - Kvartalsrapport 2013-Q3
2013-08-28 - Kvartalsrapport 2013-Q2
2013-06-17 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2013-06-14 - Årsstämma
2013-05-17 - Kvartalsrapport 2013-Q1
2013-02-22 - Bokslutskommuniké 2012
2012-11-30 - Kvartalsrapport 2012-Q3
2012-07-31 - Kvartalsrapport 2012-Q2
2012-06-20 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2012-06-19 - Årsstämma
2012-04-20 - Kvartalsrapport 2012-Q1
2012-02-21 - Bokslutskommuniké 2011
2011-11-04 - Kvartalsrapport 2011-Q3
2011-08-12 - Kvartalsrapport 2011-Q2
2011-05-06 - Kvartalsrapport 2011-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
iZafe Group är ett Life Science-bolag inriktat på utveckling och marknadsföring av digitala medicinska lösningar för läkemedelshantering i hemmet. Bolaget erbjuder produkter som Dosell, en läkemedelsrobot, och SaaS-lösningen Pilloxa, en uppkopplad dosettask. Produkterna ämnar minska risken för felmedicinering. Kunderna utgörs av privatpersoner, läkemedelsbolag samt offentliga och privata vårdgivare i Sverige, Norden och globalt. iZafe Group har sitt huvudkontor i Stockholm.
2025-02-06 08:30:00

2025 has started on a positive note for iZafe Group, with steady growth in Dosell and increasing demand across multiple markets. To provide better insights into our journey and progress, we are launching a monthly newsletter to share more frequent updates on developments behind the scenes.

If you are not yet receiving these updates via email, be sure to subscribe at the bottom of our website or through the link in our latest LinkedIn post. Follow us on LinkedIn for continuous updates.

Continuous Growth and Key Milestones
The number of billable Dosell units increased by 25% from December to January, a clear sign that our strategy and partnerships are driving demand.

Our growth is still from a smaller scale, but it is steadily increasing, bringing us closer to a key milestone of 1,000 active Dosell units in use. We expect to reach this soon, marking a significant step in our expansion.

Our business model is based on partners purchasing and stocking Dosell, ensuring cost coverage at the time of sale. The long-term value is generated when the units are activated, creating a recurring monthly revenue stream.

We have already shipped 2,500 Dosell units to our partners, who are experiencing strong demand and expect to activate them within 3–6 months. This increasing activation rate drives our revenue stream, creating a stable and scalable business model.

Sweden: Strong Momentum in VGR and More Municipalities Adopting Dosell
Dosell usage in Västra Götaland Region (VGR) has increased by 18% since December, and interest from municipalities continues to grow. We now have seven new municipalities scheduled for implementation in Q1, both within and outside VGR.

Our partners are actively driving Dosell through existing framework agreements, which accelerates deployment. To meet rising demand and support municipalities with implementation, we will host a webinar for VGR municipalities on March 6 in collaboration with ATEA.

At the MVTe trade fair, Dosell continued to generate strong interest from municipalities and private healthcare providers. Several follow-up meetings are scheduled in February.

Here are just a few comments from Swedish municipal staff, caregivers, and users about Dosell:

"We placed a Dosell with a user who was very skeptical at first. But after just a few days, she was thrilled that she could manage her medication independently while knowing that home care had full control in case she forgot."

"Our municipal staff was highly impressed after seeing Dosell presented. Compared to the larger, more complicated devices we previously used, Dosell will greatly simplify daily work."

"It is so easy to learn!"

"Using Dosell was the best decision we made. My father feels secure, and I receive alerts if anything deviates."

"When many other things started to become difficult due to memory loss, medication management continued to function thanks to Dosell."


Norway: Faster Implementation Through Partnerships
In Norway, we have partnered with Randstad to accelerate implementations and ensure optimal Dosell usage throughout contract periods.
In January, we conducted a comprehensive training session with Hepro, Careium AS, and Randstad to ensure a smooth rollout and equip their sales teams with the right tools for driving adoption.

Netherlands: Stable and Long-Term Growth
The Netherlands continues to be a key market with steady growth in Dosell adoption. Our partner has successfully integrated Dosell into its own platform, "Dispenze", which has been highly appreciated by customers. More organizations are now replacing competing solutions with Dosell.

A testament to our partner’s long-term commitment is their investment in a Dosell showroom, office, and branded delivery vehicles.

Follow TCCN on LinkedIn for regular insights and updates on how Dosell is used in the Netherlands.

Spain: Launch Around the Corner
Ti-medi has developed a comprehensive system and e-commerce solution to ensure a successful Dosell launch in Spain. The process has taken longer than expected, but we anticipate the launch happening in February.

Product Development: Improvements Drive Demand
Over the past year, we have released 13 software versions, and we are soon launching version 14, which includes significant enhancements.

Our goal has always been clear: Dosell should be simple and reliable for users, while we continuously improve refill processes, integrations, and the overall experience for caregivers and partners.

These ongoing improvements have been key to the growth we see today. Dosell is now more efficient than ever, which in turn drives increased demand.

Capital Raise and Focus on Profitability
We would also like to take this opportunity to thank our major shareholders for their support in the directed share issue of approximately SEK 9.2 million.

This capital injection strengthens our ability to accelerate growth while maintaining a clear focus on cost efficiency and achieving cash flow profitability.

We look forward to sharing more details in our upcoming quarterly report next week – stay tuned!